Home/Filings/4/0000950170-24-077522
4//SEC Filing

Brown Ryan Edward 4

Accession 0000950170-24-077522

CIK 0000873303other

Filed

Jun 24, 8:00 PM ET

Accepted

Jun 25, 8:00 PM ET

Size

29.8 KB

Accession

0000950170-24-077522

Insider Transaction Report

Form 4
Period: 2024-06-21
Brown Ryan Edward
SVP, General Counsel
Transactions
  • Sale

    Common Stock

    2024-06-25$162.65/sh17,581$2,859,55023,518 total
  • Award

    Performance Stock Units

    2024-06-21+5,5005,500 total
    Common Stock (5,500 underlying)
  • Exercise/Conversion

    Common Stock

    2024-06-21+6,25034,938 total
  • Exercise/Conversion

    Common Stock

    2024-06-25$62.77/sh+23,500$1,475,09556,086 total
  • Sale

    Common Stock

    2024-06-25$158.07/sh7,644$1,208,28748,442 total
  • Sale

    Common Stock

    2024-06-25$161.82/sh4,168$674,46641,099 total
  • Sale

    Common Stock

    2024-06-25$164.52/sh2,549$419,36117,129 total
  • Tax Payment

    Common Stock

    2024-06-24$164.64/sh2,352$387,23332,586 total
  • Sale

    Common Stock

    2024-06-25$159.14/sh2,200$350,10846,242 total
  • Sale

    Common Stock

    2024-06-25$163.53/sh3,840$627,95519,678 total
  • Exercise/Conversion

    Performance Stock Units

    2024-06-216,2500 total
    Common Stock (6,250 underlying)
  • Exercise/Conversion

    Stock Option (right to buy)

    2024-06-2523,5000 total
    Exercise: $62.77From: 2019-02-28Exp: 2028-02-28Common Stock (23,500 underlying)
  • Sale

    Common Stock

    2024-06-25$160.31/sh975$156,30245,267 total
  • Award

    Performance Stock Units

    2024-06-21+6,2506,250 total
    Common Stock (6,250 underlying)
Footnotes (10)
  • [F1]Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU.
  • [F10]Represents the number of shares earned under a PSU award granted to the Reporting Person on March 7, 2022. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 7, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date.
  • [F2]Shares were sold by the Company to satisfy tax withholding obligations related to vesting of PSUs granted on March 1, 2024.
  • [F3]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2024.
  • [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $157.58 to $158.52, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
  • [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.67 to $159.66, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
  • [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.71 to $160.69, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
  • [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $161.04 to $162.02, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
  • [F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $162.12 to $163.09, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
  • [F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.19 to $163.98 inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Documents

1 file

Issuer

Sarepta Therapeutics, Inc.

CIK 0000873303

Entity typeother

Related Parties

1
  • filerCIK 0001848718

Filing Metadata

Form type
4
Filed
Jun 24, 8:00 PM ET
Accepted
Jun 25, 8:00 PM ET
Size
29.8 KB